Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety, PK/PD and immunogenicity study of ONO-4915 in Japanese healthy adult males
jRCT2071240056Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of ONO-4915 in autoimmune disease (6 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Safety and tolerability of ONO-4915 and Pharmacokinetics of ONO-4915. Started Nov 2024; status: completed.
02
Drugs
ONO-4915
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on jRCT2071240056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240056.